Arkema Receives Regulatory Approval to Market Carbon Nanotubes in US

Arkema now has received EPA (Environmental Protection Agency) approval for commercial sales of its Graphistrength® multiwall carbon nanotubes (CNTs) in the United States.

This approval gives the green light to Arkema Inc., Arkema’s US subsidiary, to assist its existing and prospective customers in the US currently conducting research and application tests involving CNTs with their commercial development on a larger scale. This should boost worldwide sales of Arkema’s Graphistrength® masterbatches, which are already available in Europe and Asia.

Since it first began producing CNTs in 2006, Arkema has sought to develop, under the trademark Graphistrength®, a whole range of high added-value masterbatches designed to optimize the performance of CNTs in polymer matrices (thermoplastic, elastomer and thermoset). Graphistrength® products offer outstanding performances: in product manufacture, they are easy to use in traditional compounding processes, and they ensure excellent dispersion of CNTs in many polymer matrices, thereby delivering remarkable electrical and mechanical properties.

In September 2009, Arkema announced the construction of a 400 ton/year CNT pilot production plant in France, confirming its global commitment to CNTs on a semi-industrial scale. The plant is due to come on stream early 2011.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.